Critical race theory tools of evaluating stock characters and counter stories can help clinicians and researchers illuminate experiences of those at the margins.
AMA J Ethics. 2022;24(3):E212-217. doi:
10.1001/amajethics.2022.212.
Dr Mollie V. Willliams joins Ethics Talk to discuss her article, coauthored with Dr Olaitan Ajisafe: “How Should Exposure Risk to Tactical Personnel Be Balanced Against Clinical and Ethical Rescue Demand?”
Dr Frederic G. Reamer joins Ethics Talk to discuss his article: “Why Care-Based, Not Carceral, Approaches to Suspects With Mental Illness Is Key to Whether We Trust Professional or State Authority Ever Again”
Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021;23(7):E563-568. doi:
10.1001/amajethics.2021.563.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"